IntrinsicIntrinsic
← All summaries

Edgewise Therapeutics, Inc.

EWTX
Financials & Chart →

Business Summary

Edgewise Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on discovering and developing precision medicines for serious muscle diseases, including rare neuromuscular and cardiac conditions. The company's core business model revolves around leveraging its proprietary, muscle-focused drug discovery platform to identify small molecule precision medicines that regulate key proteins in muscle tissue. Revenue generation is currently absent, as the company has no products approved for commercial sale and anticipates it will be a couple of years, if ever, before product sales generate revenue . The primary customer segments are patients suffering from rare muscular dystrophies and severe cardiac diseases.

The company's pipeline includes several clinical-stage and preclinical programs. Sevasemten, the most advanced product candidate, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address contraction-induced muscle injury in dystrophinopathies like Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company estimates approximately 35,000 individuals live with Duchenne and 12,000 with Becker in the US, EU-5, and Japan . Sevasemten has received Fast Track designation for Duchenne in February 2024 and for Becker previously, along with Orphan Drug Designation (ODD) for Duchenne and Becker and Rare Pediatric Disease Designation (RPDD) for Duchenne in November 2023 . The European Medicines Agency (EMA) also granted ODD for sevasemten for Becker and Duchenne in April 2024 .

In its cardiovascular program, EDG-7500 is a novel oral, selective, cardiac sarcomere modulator (CSM) designed to slow early contraction velocity and address impaired cardiac relaxation in hypertrophic cardiomyopathy (HCM) without impacting systolic function. EDG-7500 is currently in a multipart Phase 2 trial for both obstructive HCM (oHCM) and nonobstructive HCM (nHCM) . A second cardiac sarcomere modulator, EDG-15400, is in a Phase 1 trial of healthy adults, with a future disease target of heart failure with preserved ejection fraction (HFpEF) . The EDG-003 discovery program is exploring candidates for cardiometabolic diseases at the preclinical stage .

For the fiscal year ended December 31, 2025, Edgewise Therapeutics reported a net loss of $167.8 million . As of December 31, 2025, the company had an accumulated deficit of $546.4 million . Cash, cash equivalents, and marketable securities totaled $530.1 million as of December 31, 2025 . The company has not generated any revenue to date .

During the reported period, Edgewise Therapeutics made several significant operational developments. In December 2024, the company reported topline data from the CANYON Phase 2 trial for sevasemten in Becker, which met its primary endpoint by demonstrating a 28% average decrease in circulating levels of CK over months 6 through 12 (p=0.02) . Plasma fast skeletal muscle troponin I (TNNI2) showed a significant decrease of 77% from baseline in the sevasemten-treated group compared to placebo (p<0.001) . Enrollment for the GRAND CANYON pivotal cohort in Becker was completed in February 2025 . In June 2025, encouraging observations were announced from the LYNX Phase 2 placebo-controlled trial in Duchenne, identifying a 10 mg dose for further evaluation . Initial results from the FOX Phase 2 placebo-controlled trial in Duchenne patients previously treated with gene therapy also supported the potential of sevasemten 10 mg to reduce the rate of functional decline . For EDG-7500, positive topline data from the Phase 1 trial in healthy subjects were announced in September 2024 . In April 2025, positive topline results from Part B and Part C of the Phase 2 CIRRUS-HCM trial in oHCM and nHCM patients were announced . In oHCM patients receiving 100 mg of EDG-7500, a 71% mean reduction in resting LVOT pressure gradient and a 58% mean reduction in provokable (Valsalva) LVOT-G were observed . Treatment with 100 mg of EDG-7500 also demonstrated a 62% mean reduction from baseline in NT-proBNP in oHCM patients , and a 42% mean reduction in NT-proBNP in nHCM patients . Enrollment in Part D of the CIRRUS-HCM trial was completed in the first quarter of 2026 .

Business Outlook

Edgewise Therapeutics expects to continue incurring significant expenses and increasing operating losses for the foreseeable future, particularly as product candidates advance through clinical development, which generally entails higher development costs due to increased size and duration of later-stage trials . The company anticipates that general and administrative expenses will increase as it scales its organization to support clinical advancement, regulatory readiness, and future commercial planning activities . The company's existing cash, cash equivalents, and marketable securities of $530.1 million as of December 31, 2025, are expected to fund current operating plans for at least the next 12 months . However, this estimate is based on assumptions that may prove incorrect, and additional funds may be needed sooner than anticipated .

A major growth area for Edgewise is the continued development and potential commercialization of sevasemten for muscular dystrophies. The company is engaging with the FDA and European Medicines Agency regarding marketing authorization filing strategies for sevasemten in Becker, based on positive Phase 2 CANYON results . The ongoing GRAND CANYON pivotal cohort, which completed enrollment in February 2025, is designed to support a marketing application, with its primary endpoint being the NSAA . For Duchenne, the LYNX trial identified a 10 mg dose for further evaluation, and initial results from the FOX trial also supported the potential of sevasemten 10 mg to reduce the rate of functional decline . The company believes sevasemten's novel mechanism of action, which selectively limits injurious stress by moderating fast skeletal muscle myosin force development, positions it as a potential foundational therapy for dystrophinopathies, either alone or in combination with other therapies .

Another key growth area is the advancement of EDG-7500 for hypertrophic cardiomyopathy (HCM). The company plans to report initial CIRRUS-HCM data from Part D in the first half of 2026 . CIRRUS-HCM Part D is designed to explore exposure-response correlations and assess biomarker-guided dose optimization to inform the design of Phase 3 trials expected in the second half of 2026 . The company believes EDG-7500's differentiated mechanism, which modulates both contraction and relaxation processes without binding to the myosin motor head, has the potential to yield a superior target product profile for HCM and may also benefit patients with heart failure with preserved ejection fraction (HFpEF) . The company plans to investigate fixed-dose regimens of EDG-7500, potentially eliminating the echo-mediated dose titration and intense follow-up requirements of current therapies .

The company also plans to initiate a Phase 2 trial for EDG-15400 in participants with HFpEF in the second half of 2026, following expected topline results from its Phase 1 trial in healthy adults in the first half of 2026 . This novel small molecule with a distinct mechanism of action is being evaluated for its potential to modulate pathways relevant to diastolic function, addressing a significant unmet medical need in HFpEF .

In terms of capital allocation, the company will require substantial additional capital to finance its operations beyond the next 12 months, as its current cash, cash equivalents, and marketable securities are not sufficient to fund any product candidates through regulatory approval . Future capital requirements will depend on factors such as the scope and costs of research and development, regulatory review, manufacturing, and commercialization activities . The company may seek additional funding through public or private equity offerings, debt financings, collaborations, and licensing arrangements . On April 3, 2025, the company closed an underwritten registered direct offering of 9,935,419 shares of common stock for net proceeds of $187.1 million .

Risk Factors

Edgewise Therapeutics faces substantial risks, including the inherent uncertainty and expense of clinical drug development, where product candidates may fail at any stage due to issues with safety, efficacy, or trial execution . The company is heavily dependent on the success of its lead product candidates, sevasemten and EDG-7500, and failure to complete their development, obtain approval, or commercialize them in a timely manner would significantly harm the business . Product candidates may cause serious adverse events or toxicities, potentially preventing regulatory approval, limiting market acceptance, or leading to significant negative consequences . The patient populations for Duchenne, Becker, and Limb-girdle muscular dystrophy (LGMD) are small and not precisely established, meaning inaccurate patient estimates or an inability to identify patients could adversely affect revenue and profitability . The regulatory approval processes are lengthy, costly, and unpredictable, with no guarantee of approval, and any delays or failures would materially harm the ability to generate product revenue . Post-marketing, approved products will be subject to significant regulatory requirements and oversight, and non-compliance could lead to sanctions, product recalls, or withdrawal from the market . The company relies on third-party contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) for production and clinical trials, increasing the risk of supply disruptions, manufacturing difficulties, or unsatisfactory performance, which could delay or impair development and commercialization efforts . Cybersecurity incidents, including data breaches or system failures, affecting the company or its third-party partners, could result in additional costs, loss of revenue, significant liabilities, and operational disruptions . Furthermore, the company's international operations expose it to economic, political, and regulatory risks, including differing regulatory requirements, trade barriers, and geopolitical conflicts such as the ongoing war in Ukraine and instability in the Middle East, which could disrupt clinical trials and supply chains . Changes in U.S. and foreign tax laws, including the Inflation Reduction Act of 2022 and the OBBB Act, could adversely affect the company's effective tax rate and operating results, potentially limiting the ability to generate revenue or attain profitability .

Management Priorities

Management emphasizes a patient-centric mission to discover new medicines for serious muscle diseases, driven by a science-focused culture that prioritizes unmet patient needs . The strategic priorities include comprehensively engaging with patients, families, and physicians to build trusted relationships and inform development programs for sevasemten, EDG-7500, EDG-15400, and other severe muscle disease programs . A key focus is leveraging clinical and regulatory precedents and extensive experience to rapidly advance sevasemten through clinical development in muscular dystrophies, aiming to establish it as a foundational therapy due to its novel mechanism of action . Management also highlights leveraging deep expertise in muscle-disease therapeutics to expand the pipeline, specifically advancing EDG-7500 for HCM and other diseases of diastolic dysfunction, anticipating a broad therapeutic index and expanded market reach . Furthermore, the company is investing in its precision medicine drug discovery platform to fuel the development of novel targeted therapies and expand into additional skeletal and cardiac muscle diseases, including the EDG-003 cardiometabolic discovery program . Opportunistically evaluating strategic collaborations and asset acquisition opportunities is also a priority to accelerate development and commercialization timelines and potentially expand the pipeline within core therapeutic areas . The company expects its current cash, cash equivalents, and marketable securities of $530.1 million to fund its current operating plan for at least the next 12 months .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  2. [2] Item 1, Business — Muscular Dystrophy
  3. [3] Item 1, Business — Muscular Dystrophy
  4. [4] Item 1A, Risk Factors — Risks Related to Regulatory Approval and Other Legal Compliance Matters
  5. [5] Item 1, Business — Cardiovascular
  6. [6] Item 1, Business — Cardiovascular
  7. [7] Item 1, Business — Preclinical
  8. [8] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  9. [9] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  10. [10] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  11. [11] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  12. [12] Item 1, Business — Phase 2 Clinical Trial in Becker (CANYON trial and GRAND CANYON cohort)
  13. [13] Item 1, Business — Phase 2 Clinical Trial in Becker (CANYON trial and GRAND CANYON cohort)
  14. [14] Item 1, Business — Phase 2 Clinical Trial in Becker (CANYON trial and GRAND CANYON cohort)
  15. [15] Item 1, Business — Phase 2 Clinical Trials in Duchenne (LYNX and FOX Studies)
  16. [16] Item 1, Business — Phase 2 Clinical Trials in Duchenne (LYNX and FOX Studies)
  17. [17] Item 1, Business — EDG-7500 Clinical Plan
  18. [18] Item 1, Business — EDG-7500 Clinical Plan
  19. [19] Item 1, Business — EDG-7500 Clinical Plan
  20. [20] Item 1, Business — EDG-7500 Clinical Plan
  21. [21] Item 1, Business — EDG-7500 Clinical Plan
  22. [22] Item 1, Business — EDG-7500 Clinical Plan
  23. [23] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  24. [24] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  25. [25] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  26. [26] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  27. [27] Item 1, Business — Phase 2 Clinical Trial in Becker (CANYON trial and GRAND CANYON cohort)
  28. [28] Item 1, Business — Phase 2 Clinical Trial in Becker (CANYON trial and GRAND CANYON cohort)
  29. [29] Item 1, Business — Phase 2 Clinical Trials in Duchenne (LYNX and FOX Studies)
  30. [30] Item 1, Business — Our Strategy
  31. [31] Item 1, Business — EDG-7500 Clinical Plan
  32. [32] Item 1, Business — EDG-7500 Clinical Plan
  33. [33] Item 1, Business — EDG-7500: A Novel Molecule for the Treatment of Patients with HCM and Other Diseases of Diastolic Dysfunction with Significant Unmet Needs
  34. [34] Item 1, Business — Our Approach and Preclinical Data
  35. [35] Item 1, Business — EDG-15400: A Novel Molecule for the Treatment of Patients with HFpEF
  36. [36] Item 1, Business — EDG-15400: A Novel Molecule for the Treatment of Patients with HFpEF
  37. [37] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  38. [38] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  39. [39] Item 1A, Risk Factors — Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
  40. [40] Item 1A, Risk Factors — Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  41. [41] Item 1A, Risk Factors — Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
  42. [42] Item 1A, Risk Factors — We are substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500.
  43. [43] Item 1A, Risk Factors — Our product candidates may cause serious adverse events, toxicities or other undesirable side effects.
  44. [44] Item 1A, Risk Factors — The patient population suffering from Duchenne, Becker and Limb-girdle muscular dystrophy (LGMD) is small and has not been established with precision.
  45. [45] Item 1A, Risk Factors — The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable.
  46. [46] Item 1A, Risk Factors — Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.
  47. [47] Item 1A, Risk Factors — We contract with third parties for the production of sevasemten, EDG-7500, and EDG-15400 for our ongoing clinical trials...
  48. [48] Item 1A, Risk Factors — Our computer systems, or those of any of our CROs, manufacturers, other contractors, consultants, service providers, or potential future collaborators, may fail or suffer security or data privacy breaches or incidents...
  49. [49] Item 1A, Risk Factors — Our business may become subject to economic, political, regulatory and other risks associated with international operations directly or indirectly.
  50. [50] Item 1A, Risk Factors — Changes in tax laws could have a material adverse effect on our business, cash flow, results of operations or financial conditions.
  51. [51] Item 1, Business — Our Strategy
  52. [52] Item 1, Business — Our Strategy
  53. [53] Item 1, Business — Our Strategy
  54. [54] Item 1, Business — Our Strategy
  55. [55] Item 1, Business — Our Strategy
  56. [56] Item 1, Business — Our Strategy
  57. [57] Item 1A, Risk Factors — We will require substantial additional capital to finance our operations.
  58. [58] Item 1A, Risk Factors — We will require substantial additional capital to finance our operations.

Analysis on 5/21/2026